retatrutide weight loss clinical trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Triple hormone receptor agonist retatrutide

But Dr Georgia Rigas, former Chair of RACGP Specific Interests Obesity Management, said the research should be interpreted with caution, adding that prescribers can help to reduce negative outcomes by providing patients with a list of symptoms to look out for and how to respond if they develop

Part D may cover drugs like Ozempic and Wegovy if theyre prescribed for diabetes management or cardiovascular disease

Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders

I figured it was another forum fantasy